gadobutrol · Bayer Hlthcare · NDA 201277

Gadavist

Earliest generic entry, as listed · earliest of 6 marketed strengths
Open now

No unexpired patents or exclusivities are listed for this product.

Listed patents · 0 unexpired

No unexpired patents listed.

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

  • Generic approved · ANDA 215957, Ge Hlthcare · 201277-001Approved 29 Jun 2026Detected 25 Oct 2026Historical import
  • Generic approved · ANDA 219287, Viwit Pharm · 201277-001Approved 11 Jun 2026Detected 25 Oct 2026Historical import
  • Generic approved · ANDA 219146, Zenara · 201277-001Approved 8 Jun 2026Detected 25 Oct 2026Historical import

Products covered · 6

NDA · productFormStrengthListed expiry
201277 · 001 · RLDsolution, intravenous4.5354GM/7.5ML (604.72MG/ML)open
201277 · 002 · RLDsolution, intravenous6.0472GM/10ML (604.72MG/ML)open
201277 · 003 · RLDsolution, intravenous9.0708GM/15ML (604.72MG/ML)open
201277 · 004 · RLDsolution, intravenous18.1416GM/30ML (604.72MG/ML)open
201277 · 005 · RLDsolution, intravenous39.3068GM/65ML (604.72MG/ML)open
201277 · 006 · RLDsolution, intravenous1.20944GM/2ML (604.72MG/ML)open